Latest Biotechnology News

Zoono Group has inked a five-year exclusive contract with Sharpak and OSY to apply its antimicrobial technology on UK soft fruit packaging, aiming to reduce food waste and boost shelf-life.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.